A Brazilian scientist's experimental paralysis therapy is fueling hope—and hype: Spinal cord injury patients are scrambling for access to the injection, but researchers say preliminary evidence is weak.

The article focuses on the experimental treatment polylaminin, developed by biologist Tatiana Sampaio and her team at the Federal University of Rio de Janeiro, aimed at promoting recovery from spinal cord injuries. A small pilot study involving eight patients, including a notable case of dramatic recovery, has generated widespread media attention and public demand in Brazil, despite concerns from researchers about the study’s limited size, lack of control groups, and potential methodological flaws. Polylaminin is a polymer derived from laminin, a protein that supports nerve fiber growth, and is intended to stimulate nerve regeneration after injury. While a phase 1 clinical trial to assess safety is underway, experts emphasize that current evidence is preliminary and does not conclusively demonstrate the treatment’s efficacy or safety. [Extracted from the article]